EFFICACY AND SAFETY OF THE SELECTIVE PROGESTERONE RECEPTOR MODULATOR (PRM) VILAPRISAN: A SUB-ANALYSIS OF THE ASTEROID 1 TRIAL BY ETHNICITY

被引：0
|
作者：
Bradley, L. D. [1 ]
Groettrup-Wolfers, E. [2 ]
Zvolanek, M.
Petersdorf, K. [3 ]
Seitz, C. [4 ]
机构：
[1] Cleveland Clin, Ob Gyn, Cleveland, OH 44106 USA
[2] Bayer, Pharmacovigilance, Berlin, Germany
[3] Bayer AG, Clin Dev, Berlin, Germany
[4] Bayer AG, Berlin, Germany
来源：
FERTILITY AND STERILITY | 2018年 / 110卷 / 04期
关键词：
D O I：
10.1016/j.fertnstert.2018.07.190
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
O-143
引用
收藏
页码：E62 / E62
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF THE SELECTIVE PROGESTERONE RECEPTOR MODULATOR (PRM) VILAPRISAN: INTEGRATED ANALYSIS OF PHASE 2 ASTEROID 1 AND 2 STUDIES.
    Danielsson, K. Gemzell
    Bradley, L. D.
    Ahlers, C.
    Faustmann, T.
    Petersdorf, K.
    Zvolanek, M.
    Groettrup-Wolfers, E.
    Seitz, C.
    FERTILITY AND STERILITY, 2018, 110 (04) : E135 - E135
  • [2] EFFICACY AND SAFETY OF THE SELECTIVE PROGESTERONE RECEPTOR MODULATOR (PRM) VILAPRISAN-24-WEEK OUTCOMES FROM ASTEROID 2
    Danielsson, K. Gemzell
    Ramirez, F.
    Petersdorf, K.
    Faustmann, T.
    Groettrup-Wolfers, E.
    Seitz, C.
    FERTILITY AND STERILITY, 2018, 110 (04) : E62 - E62
  • [3] Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women
    Schultze-Mosgau, Marcus-Hillert
    Schuett, Barbara
    Hafner, Frank-Thorsten
    Zollmann, Frank
    Kaiser, Andreas
    Hoechel, Joachim
    Rohde, Beate
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 16 - 24
  • [4] Pharmacodynamic Effects and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Healthy Women
    Rohde, Beate
    Seitz, Christian
    Kaiser, Andreas
    Schultze-Mosgau, Marcus
    Schutt, Barbara
    REPRODUCTIVE SCIENCES, 2015, 22 : 88A - 88A
  • [5] Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women
    Liu, Hongzhong
    Jiang, Ji
    Chen, Zhaozhao
    Zhang, Yunhui
    Li, Jinyi
    Hoechel, Joachim
    Rohde, Beate
    Zimmermann, Torsten
    Schultze-Mosgau, Marcus-Hillert
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (05): : 486 - 493
  • [6] Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
    Schultze-Mosgau, Marcus-Hillert
    Lasseter, Kenneth C.
    Marbury, Thomas
    Loewen, Stephanie
    Riecke, Kai
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (08): : 1030 - 1038
  • [7] Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids
    Magnay, Julia L.
    FERTILITY AND STERILITY, 2019, 111 (02) : 249 - 250
  • [8] Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women
    Schutt, Barbara
    Kaiser, Andreas
    Schultze-Mosgau, Marcus-Hillert
    Seitz, Christian
    Bell, David
    Koch, Manuela
    Rohde, Beate
    HUMAN REPRODUCTION, 2016, 31 (08) : 1703 - 1712
  • [9] Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-1 Randomized Controlled Trial
    Kitazono, Takanari
    Toyoda, Kazunori
    Kitagawa, Kazuo
    Nagao, Takehiko
    Yamagami, Hiroshi
    Uchiyama, Shinichiro
    Tanahashi, Norio
    Matsumoto, Masayasu
    Minematsu, Kazuo
    Nagata, Izumi
    Nishikawa, Masakatsu
    Nanto, Shinsuke
    Ikeda, Yasuo
    Shirai, Toshiaki
    Abe, Kenji
    Ogawa, Akira
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2021, 28 (02) : 169 - 180
  • [10] Efficacy and Safety of Ferric Derisomaltose in Older Patients: A Sub-Analysis of The FERWON-IDA Trial
    Ershler, W.
    Smoor, R.
    Noordzij, P.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S86 - S86
12345